CN105622754B - Fc受体结合蛋白 - Google Patents

Fc受体结合蛋白 Download PDF

Info

Publication number
CN105622754B
CN105622754B CN201510926183.4A CN201510926183A CN105622754B CN 105622754 B CN105622754 B CN 105622754B CN 201510926183 A CN201510926183 A CN 201510926183A CN 105622754 B CN105622754 B CN 105622754B
Authority
CN
China
Prior art keywords
antibody
seq
fcrn
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510926183.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105622754A (zh
Inventor
D·J·塞克斯顿
C·汤乎尔
M·维斯瓦纳坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
DEX Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DEX Co Ltd filed Critical DEX Co Ltd
Publication of CN105622754A publication Critical patent/CN105622754A/zh
Application granted granted Critical
Publication of CN105622754B publication Critical patent/CN105622754B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201510926183.4A 2011-06-02 2012-06-01 Fc受体结合蛋白 Active CN105622754B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161492617P 2011-06-02 2011-06-02
US61/492,617 2011-06-02
US201161498266P 2011-06-17 2011-06-17
US61/498,266 2011-06-17
CN201280031902.0A CN103619353B (zh) 2011-06-02 2012-06-01 Fc受体结合蛋白

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280031902.0A Division CN103619353B (zh) 2011-06-02 2012-06-01 Fc受体结合蛋白

Publications (2)

Publication Number Publication Date
CN105622754A CN105622754A (zh) 2016-06-01
CN105622754B true CN105622754B (zh) 2019-12-27

Family

ID=47259886

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280031902.0A Active CN103619353B (zh) 2011-06-02 2012-06-01 Fc受体结合蛋白
CN201510926183.4A Active CN105622754B (zh) 2011-06-02 2012-06-01 Fc受体结合蛋白

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201280031902.0A Active CN103619353B (zh) 2011-06-02 2012-06-01 Fc受体结合蛋白

Country Status (14)

Country Link
US (6) US9359438B2 (cg-RX-API-DMAC7.html)
EP (2) EP2966089B1 (cg-RX-API-DMAC7.html)
JP (3) JP6104897B2 (cg-RX-API-DMAC7.html)
KR (1) KR102014554B1 (cg-RX-API-DMAC7.html)
CN (2) CN103619353B (cg-RX-API-DMAC7.html)
AU (2) AU2012262007B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030352B1 (cg-RX-API-DMAC7.html)
CA (1) CA2837527C (cg-RX-API-DMAC7.html)
ES (1) ES2748583T3 (cg-RX-API-DMAC7.html)
IL (1) IL229618B (cg-RX-API-DMAC7.html)
MX (1) MX343659B (cg-RX-API-DMAC7.html)
PH (1) PH12013502378A1 (cg-RX-API-DMAC7.html)
SG (2) SG195025A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012167039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722082C (en) * 2008-04-25 2021-11-09 Christopher Tenhoor Fc receptor binding proteins
PH12013502378A1 (en) 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
EP3663763B1 (en) * 2013-11-26 2022-02-16 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
PT3137504T (pt) * 2014-04-30 2023-08-18 Hanall Biopharma Co Ltd Anticorpo que se liga a fcrn para tratar doenças autoimunes
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
SG11201705475QA (en) * 2015-01-30 2017-08-30 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
AU2017257680A1 (en) * 2016-04-25 2018-12-06 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
IL302288B2 (en) * 2016-07-29 2025-09-01 Momenta Pharmaceuticals Inc FCRN antibodies and methods of using them
CN110023120A (zh) 2016-12-01 2019-07-16 Sabic环球技术有限责任公司 组合的复合尾门
BR112019026694A2 (pt) * 2017-06-15 2020-06-23 UCB Biopharma SRL Método para o tratamento da trombocitopenia imune
AU2018380979B2 (en) 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
BR112020011310A2 (pt) * 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
MX2020013195A (es) 2018-06-08 2021-02-26 Argenx Bvba Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.
BR112021000755A2 (pt) * 2018-07-20 2021-04-13 Momenta Pharmaceuticals, Inc. Composições de anticorpo de fcrn
US20230287107A1 (en) * 2019-07-23 2023-09-14 Shanghaitech University Asic1 channel antagonist antibody
CN115836086A (zh) 2020-01-08 2023-03-21 阿尔金克斯有限公司 治疗天疱疮病症的方法
WO2021257668A1 (en) 2020-06-17 2021-12-23 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
EP4323766A1 (en) * 2021-04-14 2024-02-21 Genentech, Inc. In vitro cell-based assay for predicting pharmacokinetics and brain penetration of biologics
CA3254741A1 (en) 2022-05-30 2023-12-07 Hanall Biopharma Co., Ltd. ANTI-FCRN ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF FCRN EXHIBITING IMPROVED STABILITY
AU2023290529A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn/antigen-binding molecules and methods of use
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588A (zh) * 2024-10-17 2025-02-21 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3875456T3 (de) 1987-11-09 1998-06-10 Becton Dickinson Co Verfahren zur Analyse hämatopoietischer Zellen in einer Probe.
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
JP2002510505A (ja) 1998-04-03 2002-04-09 フィロス インク． 位置特定可能な蛋白質アレイ
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
ATE510561T1 (de) 2002-03-04 2011-06-15 Imclone Llc Kdr-spezifische menschliche antikörper und ihre verwendung
US20050079169A1 (en) * 2003-08-08 2005-04-14 Balthasar Joseph P. Anti-FcRn antibodies for treatment of auto/allo immune conditions
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
US20100266530A1 (en) 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
CA2637929A1 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US20070181136A1 (en) 2006-02-08 2007-08-09 Gelb Michael L Oral appliance
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
PH12021552811A1 (en) 2007-09-26 2022-11-21 Chugai Pharmaceutical Co Ltd Modified antibody constant region
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CA2722082C (en) 2008-04-25 2021-11-09 Christopher Tenhoor Fc receptor binding proteins
US8537763B2 (en) 2008-06-30 2013-09-17 Motorola Mobility Llc Frame allocation to support legacy wireless communication protocols on uplink transmission
EP2322610B1 (en) * 2008-07-16 2016-12-14 Medical and Biological Laboratories Co., Ltd. Anti-human clcp1 antibody and use thereof
TW201029662A (en) * 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
US9228017B2 (en) * 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
PH12013502378A1 (en) 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
WO2018224951A2 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
MX2020013195A (es) 2018-06-08 2021-02-26 Argenx Bvba Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.

Also Published As

Publication number Publication date
WO2012167039A1 (en) 2012-12-06
US11014988B2 (en) 2021-05-25
JP6638018B2 (ja) 2020-01-29
HK1213905A1 (en) 2016-07-15
US20140308206A1 (en) 2014-10-16
US10479834B2 (en) 2019-11-19
US20200109199A1 (en) 2020-04-09
SG195025A1 (en) 2013-12-30
BR112013030352B1 (pt) 2020-05-19
US11739152B2 (en) 2023-08-29
PH12013502378A1 (en) 2014-01-06
EP2714084A1 (en) 2014-04-09
EP2966089A1 (en) 2016-01-13
JP2017169559A (ja) 2017-09-28
US20240124593A1 (en) 2024-04-18
CN103619353B (zh) 2016-01-06
NZ715057A (en) 2017-09-29
CN103619353A (zh) 2014-03-05
KR20140036267A (ko) 2014-03-25
US9862768B2 (en) 2018-01-09
AU2012262007B2 (en) 2017-06-22
JP2014523737A (ja) 2014-09-18
US12454575B2 (en) 2025-10-28
AU2017232160B2 (en) 2019-12-19
AU2017232160A1 (en) 2017-10-12
US20180305454A1 (en) 2018-10-25
EP2714084B1 (en) 2019-05-22
KR102014554B1 (ko) 2019-08-26
US9359438B2 (en) 2016-06-07
IL229618A0 (en) 2014-01-30
JP6334763B6 (ja) 2018-07-11
MX343659B (es) 2016-11-16
BR112013030352A2 (pt) 2017-08-01
US20160304608A1 (en) 2016-10-20
CA2837527C (en) 2019-05-28
CN105622754A (zh) 2016-06-01
SG10201604493TA (en) 2016-07-28
JP2018121657A (ja) 2018-08-09
US20210309741A1 (en) 2021-10-07
MX2013013832A (es) 2014-05-20
NZ618046A (en) 2016-02-26
EP2966089B1 (en) 2020-03-25
CA2837527A1 (en) 2012-12-06
EP2714084A4 (en) 2014-11-19
IL229618B (en) 2018-10-31
JP6104897B2 (ja) 2017-04-05
HK1195260A1 (zh) 2014-11-07
ES2748583T3 (es) 2020-03-17
JP6334763B2 (ja) 2018-05-30

Similar Documents

Publication Publication Date Title
US12454575B2 (en) Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies
EP3670538A1 (en) Antibodies against fcrn and use thereof
AU2012262007A1 (en) Fc receptor binding proteins
HK40031845A (en) Antibodies against fcrn and use thereof
HK1225394A (en) Fc receptor binding proteins
HK1225394A1 (en) Fc receptor binding proteins
NZ715057B2 (en) Fc Receptor Binding Proteins
HK1213905B (en) Fc receptor binding proteins
HK1196545B (en) Fc receptor binding proteins
HK1196545A (en) Fc receptor binding proteins
HK1195260B (en) Fc receptor binding proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1225394

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210621

Address after: 1-1, sidingmu, xiudaocho, Central District, Osaka, Japan

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Patentee before: Daix GmbH

TR01 Transfer of patent right